In a dramatic industry confrontation, pharmaceutical giant Eli Lilly is making strategic moves that could reshape market dynamics. The company announced it will transition approximately 50,000 employees to a new pharmacy benefits provider starting January 2026, following CVS Health’s decision to remove Lilly’s weight-loss medication Zepbound from its preferred drug list. This decisive action sends an unmistakable message to pharmacy benefit managers: excluding Lilly products comes with significant business consequences.
Strategic Shift to Rightway Healthcare
The transition to Rightway, a technology-focused pharmacy services provider, represents more than just a vendor change. This move comes as direct response to CVS Caremark’s May 2025 decision to drop Zepbound from its formulary in favor of Novo Nordisk’s competing Wegovy treatment, apparently securing better pricing terms with the Danish manufacturer.
Industry analysts view Lilly’s workforce transition as indicative of shifting power dynamics within the healthcare sector. Large pharmaceutical manufacturers are increasingly pushing back against the influence of pharmacy benefit managers, who have traditionally controlled which medications patients can access through their insurance coverage.
Government Agreement Expands Access
Simultaneously with its CVS departure, Eli Lilly secured a landmark arrangement with U.S. government health programs. Announced November 6, 2025, this agreement establishes that Medicare beneficiaries will pay no more than $50 monthly for Zepbound starting April 2026—a substantial reduction from previous costs. The deal also expands Medicaid patient access to the medication.
Perhaps most significantly, the government arrangement includes coverage for Orforglipron, Lilly’s experimental once-daily obesity treatment in pill form. The company has requested an accelerated approval pathway that could reduce the standard 10-12 month review period to just 1-2 months.
CEO David A. Ricks characterized the agreement as a “pivotal moment in U.S. healthcare policy.” Collaboration with the Trump administration could potentially provide millions of Americans with access to advanced obesity treatments while positioning Lilly with considerable competitive advantage against Novo Nordisk.
Record-Breaking Quarterly Performance
These strategic developments build upon exceptionally strong operational results. Third-quarter 2025 financials surpassed all expectations, with revenue surging 54% to $17.6 billion.
GLP-1 medications drove particularly impressive results:
– Mounjaro (diabetes): Quarterly revenue of $6.52 billion—nearly one billion above analyst projections
– Zepbound (obesity): Generated $3.59 billion in sales
– International Mounjaro sales: Approximately one billion higher than Guggenheim estimates
Based on this robust performance, management raised full-year 2025 guidance, projecting revenue between $63.0 and $63.5 billion with adjusted earnings per share expected to reach $23.00 to $23.70.
Should investors sell immediately? Or is it worth buying Eli Lilly?
Analyst Upgrades and Price Target Increases
The positive developments prompted Leerink Partners to upgrade Eli Lilly shares from “Market Perform” to “Outperform” on November 10, simultaneously raising their price target from $886 to $1,104. The investment bank cited expanded Medicare and Medicaid coverage as likely to trigger multiple waves of adoption for obesity treatments.
Following this upgrade, shares reached new 52-week highs, extending an impressive rally that included 16% gains over the previous month.
Manufacturing Expansion Supports Growth Ambitions
Eli Lilly is supporting its growth trajectory with substantial manufacturing investments. On November 3, the company revealed plans for a $3 billion production facility in Katwijk, Netherlands, focused on oral medications including Orforglipron. The project is expected to create 500 high-wage positions plus 1,500 construction jobs.
This announcement followed closely an October 29 disclosure of a $1.2 billion expansion to Lilly’s Puerto Rico facility. These investments demonstrate the company’s commitment to avoiding supply constraints that have previously hampered competitor Novo Nordisk.
Industry Implications of the CVS Separation
The break with CVS transcends a simple contract dispute, representing a fundamental shift in pharmaceutical industry dynamics. Major manufacturers like Lilly are increasingly resisting the pricing power wielded by pharmacy benefit managers, who have historically influenced which medications patients receive.
Market observers interpret Lilly’s decisive action as an industry warning: entities that work against major pharmaceutical companies’ interests risk losing valuable business relationships. For CVS, the departure represents both reputational impact and the loss of a significant customer account.
Future Catalysts and Pipeline Development
Investors are monitoring several upcoming developments, including anticipated regulatory submission for Orforglipron by year-end 2025, implementation of Medicare pricing in April 2026, and continued international expansion of Mounjaro.
Beyond its GLP-1 portfolio, Eli Lilly is strengthening other therapeutic areas. November 6 appointments of Dr. Carole Ho to lead neuroscience and Adrienne Brown as president of immunology position the company for sustained growth across multiple treatment categories, ensuring long-term diversification beyond current blockbuster medications.
Ad
Eli Lilly Stock: Buy or Sell?! New Eli Lilly Analysis from November 12 delivers the answer:
The latest Eli Lilly figures speak for themselves: Urgent action needed for Eli Lilly investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 12.
Eli Lilly: Buy or sell? Read more here...
